



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Rabbit anti-CD99, clone EPR3097Y

Clone no. EPR3097Y

MONOSAN Ready To Use

Product name	Rabbit anti-CD99, clone EPR3097Y
Host	Rabbit
Applications	IHC-P
Species reactivity	human
Conjugate	-
Immunogen	Unknown or proprietary to MONOSAN and/or its suppliers
Isotype	IgG
Clonality	Monoclonal
Clone number	EPR3097Y
Size	7 ml
Concentration	n/a
Format	-
Storage buffer	Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide
Storage until expiry date	2-8°C

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES

Rabbit anti-CD99, clone EPR3097Y

Clone no. EPR3097Y

MONOSAN Ready To Use

Additional info

CD99, as detected with a variety of antibodies, is expressed by virtually almost all Ewings sarcoma and primitive peripheral neuroectodermal tumors (ES/PNET) and demonstrates strong and diffuse membranous staining. Other tumors that may show CD99 expression include neuroendocrine carcinomas, mesenchymal chondrosarcomas, solitary fibrous tumors, synovial sarcomas, vascular tumors, small round blue cell tumors, lymphoblastic lymphoma, acute myeloid leukemia, and myeloid sarcoma.⁵ However, strong and diffuse membranous reactivity for CD99 favors ES/PNET over the other diagnostic considerations. The other CD99+ tumors usually show cytoplasmic and more heterogeneous staining. Therefore, when making a final diagnostic interpretation, CD99 must be considered in a panel with other antibodies.

References

1. Rettig WJ, et al. Lab Invest. 1992; 66:133
2. Fellingner EJ, et al. Amer J Surg Pathol. 1992; 16:746
3. Ambros IM, et al. Cancer. 1991; 139:317
4. Khoury JD. Adv Anat Pathol. 2005; 12:212-20
5. Dabbs DJ. Theranostic and Genomic Applications. 2014; 126

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES